Thalidomide as salvage therapy for chronic graft-versus-host disease.
نویسندگان
چکیده
Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD). To determine the efficacy of this agent in patients with refractory CGVHD a total of 80 patients who failed to respond to prednisone (PSE) or PSE and cyclosporine (CSA) were treated with thalidomide. Sixteen patients (20%) had a sustained response, 9 with a complete remission and 7 with a partial response. Twenty-nine patients (36%) had thalidomide discontinued because of side effects, which included sedation, constipation, neuritis, skin rash, and neutropenia. Side effects were reversible with drug discontinuation except for mild residual neuritis in one case. Rashes and neutropenia have not previously been reported as thalidomide side effects when used for CGVHD treatment. We conclude thalidomide is immunosuppressive and active in the treatment of CGVHD. A high incidence of reversible side effects limited dose intensity and reduced the number of patients who could benefit from treatment.
منابع مشابه
Treatment of chronic cutaneous graft versus host disease (GVHD) with photochemotherapy with Psoralen (PUVA): A report of five cases
Chronic graft versus host disease (GVHD) remains the most common late complication of allogenic stem cell transplantation and the most frequent cause of morbidity and mortality in these patients. To control this condition, immunosuppressive drugs are usually administered at a high dose and for a long time, which may result in several side effects. 5 patients with clinically and histopathologica...
متن کاملLow Dose Psoralen Plus Ultraviolet A (PUVA) Is an Effective and Safe Method for the Treatment of Chronic Graft Versus Host Disease
Background: Chronic graft versus host disease (ch.GVHD) is the most frequent late complication after allogenic stem-cell transplantation. Systemic immunosuppressive agents are usually required to control the disease. Psoralen plus UVA (PUVA) has been used for the treatment of ch.GVHD with variable beneficial effects. The objective of this study was to assess the efficacy and safety of a r...
متن کاملThalidomide for treatment of patients with chronic graft-versus-host disease.
In a randomized, placebo-controlled, double-blind trial, thalidomide or placebo together with glucocorticoids and either cyclosporine or tacrolimus was administered as initial therapy for clinical extensive chronic graft-versus-host disease (cGVHD). All patients had thrombocytopenia or cGVHD that evolved directly from acute GVHD as an indicator of a poor prognosis. The study drug (thalidomide o...
متن کاملRediscovering Thalidomide
Thalidomide, a hypnosedative drug introduced in the 1950, has been used in a variety of dermatologic conditions during the past few decades. Although originally withbrawn from world market on discovery of its teratogenic effect, it has since been selectively reintroduced for use in various disorders thought to have an autoimmune or inflammatory basis. A review of the literature focused on clini...
متن کاملEvaluation of narrow band UVB therapeutic effect on chronic mucocutaneous graft versus host disease lesions: A case series
Background: Chronic graft versus host disease (cGVHD) is a major cutaneous complication of bone marrow transplantation (BMT). Although milder forms of this process may be associated with a lower incidence of tumor recurrences, it is mandatory to develop a more efficient and less harmful therapeutic approach.Methods: This case-series study enrolled 7 patients diagnosed with chronic mucocutaneous...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Blood
دوره 86 9 شماره
صفحات -
تاریخ انتشار 1995